Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Last traded Feb 6, 2026. This price is not current.
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for Generation Bio Co.
How GBIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Readouts, endpoints and source filings for every GBIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| T cell-mediated autoimmune diseases | 2024-11-06 | a single IV dose of a ctLNP delivering mRNA selectively to T cells transduced most circulating T cells with balanced distribution to CD4+ and CD8+ cells; confirm and improve on the potency and biodistribution profiles seen in previous murine and NHP studies; minimal off-target distribution to LNP clearance tissuesRead More | Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticleRead More |
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Conway Kevin JohnOfficer (Chief Financial Officer) | Option | 235 2,144 held | $0.00 | 02/02/2026 |
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 0.2 % | 1.76 M | 310.00 K |
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How GBIO ranks across every disease it competes in